RxDoctor Payments Data

Emily Blackmore

Adult Health · Columbus, OHNPI 1659620490

Payments from drug & device makers

$1,774in general payments, 2019–2025

Across 43 payments — averaging $41.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$407
  • Novo Nordisk$336
  • Corcept Therapeutics$335
  • Sequel Med Tech, LLC$163
  • Lilly USA, LLC$158
  • Abbott$157
  • plus $217 from 6 others

What the payments were for

  • Food & beverage$1,74598%
  • Education$292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,774 in reported general payments places this provider in the 75th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$33,728
Medicare patients
231
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide196$278,151
OzempicSemaglutide179$253,542
JardianceEmpagliflozin146$208,614
MounjaroTirzepatide111$134,681
FarxigaDapagliflozin Propanediol134$128,579
Tresiba Flextouch U-200Insulin Degludec57$72,367
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$41,638
TradjentaLinagliptin37$39,067
Bydureon BciseExenatide Microspheres28$39,003
RybelsusSemaglutide22$35,508
Humalog Kwikpen U-200Insulin Lispro11$30,185
Tresiba Flextouch U-100Insulin Degludec50$25,816
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$24,317
JanuviaSitagliptin Phosphate17$23,190
Humalog Kwikpen U-100Insulin Lispro51$22,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$158$412,832307 claims
Novo NordiskOzempic, Rybelsus$336$289,050201 claims
AstraZenecaFarxiga$407$128,579134 claims
Cequr CorporationCequr Simplicity$80$4,43611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,184 adult health providers in Ohio.

Other adult health in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →